IDEAYA Biosciences (NasdaqGS:IDYA) 2025 Conference November 18, 2025 08:00 AM ET Company ParticipantsYujiro Hata - CEOConference Call ParticipantsMaury Rycroft - AnalystMaury RycroftHi everyone, my name is Maury Rycroft, and one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Yujiro Hata, the CEO of IDEAYA Biosciences. Thanks so much for joining us today, Yujiro. We're going to do a fireside chat format. For those who may be new to the story, if you can give a one-min ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 自願性公告 與沃森的諒解備忘錄 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 – 1 – 諒解備忘錄 進行諒解備忘錄項下合作的理由及裨益 本公司董事（「董事」）會（「董事會」）宣佈，本公司近期與雲南沃森生物技術股 份有限公司（「沃森」）訂立了一份諒解備忘錄（「諒解備忘錄」），據此，訂約方已 同意發揮各自的互補優勢，就創建以RNA為中心的預防及精準醫療平台建立戰 略合作夥伴關係，並涵蓋共同開發、臨床試驗及註冊以及銷售及分銷。諒解備 忘錄的期限自簽署日期（包括該日）起為期兩年。 有關沃森的資料 沃森成立於2001年，是中國領先的高科技生物製藥 ...

来源：新浪证券-红岸工作室 11月18日，君实生物跌1.76%，成交额2.74亿元，换手率0.95%，总市值383.98亿元。 异动分析 创新药+生物疫苗+猴痘概念 1、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in-class（同类最优） 的药物。 通过卓越的创新药物发现能力、 强大的生物技术研 发能力和大规模生产能力， 公司已成功开发出极具市场潜力的药品组合， 多项产品具有里程碑意义： 核心产品之一特瑞普利单抗是国内首个获得 NMPA 批准上市的国产抗 PD-1 单克隆抗体， 截至本报告 披露日已在中国内地获批 11 项适应症， 另有一项 sNDA 已受理， 其中多项为公司独家或领先适应 症， 特瑞普利单抗还是 FDA 批准上市的首个中国自主研发和生产的创新生物药， 截至本报告披露日， 特瑞普利单抗已在中国内地、 中 ...

撰文丨王聪 该研究开发了 按需挤出 （ extrusion-on-demand， EoD ） 生物打印技术，构建出具有微米级结构保真度 （内膜、中膜和外膜） 与可定制宏观 几何形状的 动脉模型 ，再现了血管疾病中的协同微环境相互作用， 可用于解析心血管疾 病机制、评估微环境特异性疗法，从而推动心血管疾病的个性化治疗革新。 编辑丨王多鱼 排版丨水成文 心血管疾病 是全球头号致死病因，然而，由于缺乏能够真实再现人体动脉复杂环境的实验室模型，预防和治 疗心血管疾病的研究一直受阻。在患者身上，血管疾病是由结构重塑、血流紊乱和炎症信号转导等多种因素 共同作用而产生的，但现有的模型却过于简化了这一现实。二维 （2D） 平面培养无法体现细胞间相互作 用，而大多数三维 （3D） 系统又缺乏天然血管所具有的分层结构和血流动力学调控机制。因此，许多基本 机制仍未得到解决，药物试验也常常无法取得预期效果。 2025 年 11 月 11 日，浙江大学 杨华勇 院士团队 周竑钊 、西湖大学 沈璐琦 、杭州师范大学 李琦 作为共同通讯作者，在 Cell 子刊 Cell Biomaterials 上发表了题为： Multiscale bi ...

IGC Pharma (NYSEAM:IGC) Q2 2026 Earnings Call November 17, 2025 11:00 AM ET Company ParticipantsRam Mukunda - CEORosalyn Christian - Head of Investor RelationsConference Call ParticipantsEdward Wu - Equity Research AnalystJames Malloy - Managing Director, and Biotechnology, and Specialty Pharmaceuticals Equity Research AnalystAdam Snyder - Senior Equity AnalystOperatorLadies and gentlemen, greetings, and welcome to the IGC Pharma mid-year fiscal 2026 shareholder update call. At this time, all participants a ...

IGC Pharma (NYSEAM:IGC) Q2 2026 Earnings Call November 17, 2025 11:00 AM ET Company ParticipantsRam Mukunda - CEORosalyn Christian - Head of Investor RelationsOperatorLadies and gentlemen, greetings, and welcome to the IGC Pharma mid-year fiscal 2026 shareholder update call. At this time, all participants are in a listen-only mode. Please note this conference is being recorded. Following management's remarks, the call line will be opened for questions. It is now my pleasure to introduce your host, Rosalyn C ...

Financial Data and Key Metrics Changes - The company reported a non-cash profit of approximately $1.1 million from the divestiture of a non-core manufacturing facility, which was sold for about $2.7 million [20][21] - The company has renewed its $12 million line of credit and is focused on minimizing dilution while maintaining a clean capital table [17] Business Line Data and Key Metrics Changes - IGC 81 is currently in a phase two trial, with over 50% enrollment completed, and the company is optimistic about finishing the trial in the first half of next year [4][9] - The CALMA trial, which focuses on agitation in Alzheimer's patients, has expanded to multiple sites in the U.S. and Canada, with a significant increase in patient recruitment [10][28] Market Data and Key Metrics Changes - The company is addressing a significant unmet need in the Alzheimer's market, with over 55 million diagnosed patients and 400 million at risk due to Alzheimer's pathology [5][16] - The company is developing an AI-based diagnostic platform, MINT-AD, aimed at early detection and prediction of cognitive decline in Alzheimer's patients [13][14] Company Strategy and Development Direction - The company is focused on advancing its multi-asset pipeline, particularly IGC 81, which is seen as a near-term opportunity to drive shareholder value [6][12] - The strategic divestiture of the Vancouver manufacturing facility allows the company to redirect resources and management attention towards accelerating the CALMA trial and advancing other small molecule assets [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in completing the CALMA trial and achieving significant milestones in the upcoming year, which they believe will enhance shareholder value [18][31] - The company is not expecting any impact from recent legislation affecting the hemp industry on its pharmaceutical development and FDA approval processes [24][25] Other Important Information - The company is in the semi-final round for a $1 million prize aimed at advancing Alzheimer's research through AI, with a presentation scheduled for December 5 [29][31] - The company has received recognition for its work, including awards from the National Institute on Aging, highlighting its commitment to Alzheimer's research [29] Q&A Session Summary Question: Will there be another interim data analysis before the trial completion? - Management indicated that they do not expect another readout and are focused on completing the trial and the final readout [20] Question: Why was the Vancouver manufacturing facility divested? - The divestiture was strategic to eliminate $600,000 in annual operating expenses and redirect resources to accelerate the CALMA trial [20][21] Question: Are there plans for Canadian approval alongside FDA approval? - Yes, the company plans to seek approval in both the U.S. and Canada as the trial is being conducted in both regions [23] Question: Will the recent government funding bill impact the phase two trial? - Management clarified that the bill targets the consumer hemp market and does not affect the regulatory pathway for prescription drugs like IGC 81 [24][25] Question: How is enrollment going for the CALMA trial? - Enrollment has significantly increased, with a rise from signing up four patients a month to 14, aided by online advertising and geotargeting [28]

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 6.28%, indicating volatility in market performance [1]. Financial Performance - For the period from January to September 2025, United Imaging Healthcare reported a revenue of 8.859 billion yuan, representing a year-on-year growth of 27.39% [2]. - The net profit attributable to shareholders for the same period was 1.120 billion yuan, showing a significant increase of 66.91% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for United Imaging Healthcare reached 32,400, an increase of 96.28% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 29.23% to 25,444 shares [2]. - The stock's trading activity showed a net outflow of 58.49 million yuan from main funds, with significant selling pressure observed [1]. Company Overview - United Imaging Healthcare, established on March 21, 2011, and listed on August 22, 2022, specializes in high-performance medical imaging equipment, radiation therapy products, and medical digital solutions [1]. - The company's revenue composition includes 81.29% from medical imaging diagnostic equipment and radiation therapy equipment sales, 13.56% from maintenance services, and 4.68% from other sources [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings [3].

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - The acquisition of Crown Bioscience International by the report's subject company,艾迪康, for a base consideration of $204 million (approximately 1.48 billion RMB), marks a strategic shift from clinical testing services to drug development, aligning with the trend of collaborative development in precision medicine [3][13] - The report emphasizes the importance of CROs possessing translational medicine capabilities to facilitate the rapid transition from preclinical biomarkers to clinical trials and diagnostic processes [3] Summary by Sections Industry Overview -艾迪康 announced the acquisition of Crown Bioscience International, a global CRO focused on oncology and immuno-oncology drug discovery and development, with the transaction expected to complete by mid-2026 [3] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as 恒瑞医药, 百济神州, and 中国生物制药, as well as companies with significant single-product potential like 一品红 and 三生制药 [5] - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as 东诚药业 and 远大医药, and suggests monitoring the CXO sector for stable growth in R&D investment [5] Market Performance - The pharmaceutical sector saw a 3.29% increase last week, ranking 4th among 28 industries, while the Hong Kong pharmaceutical sector rose by 6.80%, ranking 2nd among 11 industries [7][30] - The report notes that the valuation of the pharmaceutical sector is currently at 30.89 times (TTM), with a premium of 22.29% over the overall A-shares [23]

Core Viewpoint - Zhaoli Pharmaceutical's stock has experienced a decline of 2.05% on November 17, with a current price of 17.23 CNY per share and a market capitalization of 12.085 billion CNY, despite a year-to-date increase of 16.67% [1] Financial Performance - For the period from January to September 2025, Zhaoli Pharmaceutical reported a revenue of 2.28 billion CNY, reflecting a year-on-year growth of 11.48%, and a net profit attributable to shareholders of 510 million CNY, which is a 21.00% increase compared to the previous year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion CNY, with 942 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,400, up by 7.31%, while the average number of circulating shares per person decreased by 6.82% to 14,562 shares [2] - Among the top ten circulating shareholders, the "Innovative Medicine" fund holds 6.8549 million shares, an increase of 280,700 shares, while the "Southern CSI 1000 ETF" holds 6.4172 million shares, a decrease of 58,800 shares [3] Stock Performance - Zhaoli Pharmaceutical's stock has seen a decline of 2.43% over the last five trading days, 6.92% over the last twenty days, and 13.29% over the last sixty days [1] - The stock's trading volume on November 17 was 58.7402 million CNY, with a turnover rate of 0.56% [1] Business Overview - Zhaoli Pharmaceutical, established on January 28, 2000, and listed on February 22, 2011, specializes in the research, production, and sales of medicinal fungi, traditional Chinese medicine pieces, and formula granules [1] - The company's main revenue sources include the Wuling series (56.07%), traditional Chinese medicine pieces (21.85%), and other products [1] Industry Classification - Zhaoli Pharmaceutical is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - The company is associated with various concept sectors, including value growth, cell therapy, precision medicine, cancer treatment, and innovative drugs [1]